Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > fda max

: 10 mg/d

or 100 mg/d

or Formulation-dependent

Use the filters below to narrow your results.

None (1) · Alprazolam (1) · Amlodipine (1) · Dapagliflozin (1) · Ezetimibe (1) · Flibanserin (1) · Losartan (1) · Sitagliptin (1) · Testosterone (1)

Addyi (1) · AndroGel, Testim, Axiron, Fortesta (gels); Androderm (patch); Aveed (IM); Striant (buccal); Natesto (nasal); Jatenzo, Tlando (oral undecanoate) (1) · Cozaar (1) · Dayvigo (1) · Farxiga (US), Forxiga (international) (1) · Januvia; with metformin Janumet/Janumet XR (1) · Norvasc, Katerzia (1) · Xanax (1) · Zetia (1)

None (2) · 5-HT1A agonist, 5-HT2A antagonist, with weaker activity at D4 and other receptors. Net effect involves enhanced prefrontal dopaminergic/noradrenergic tone with decreased serotonergic inhibition of sexual desire. (1) · Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. (1) · Endogenous androgen binding to androgen receptors; mediates male secondary sex characteristics, anabolism, libido, erythropoiesis, and CNS effects on mood/energy/aggression. Aromatized peripherally to estradiol; reduced to DHT. (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · '"`UNIQ--vote-00000073-QINU`"' The long half-life gives smooth, once-daily BP control with low rebound. CYP3A4 substrate; pedal edema is the characteristic, dose-related, non-fluid-overload side effect'"`UNIQ--ref-00000074-QINU`"'. (1) · '"`UNIQ--vote-000000B6-QINU`"' Active metabolite EXP3174 is ~10-40-fold more potent than the parent and accounts for most of the antihypertensive effect; CYP2C9 polymorphism affects conversion'"`UNIQ--ref-000000B7-QINU`"'. (1) · '"`UNIQ--vote-00000762-QINU`"' Largely renally cleared, hence the eGFR-tiered dosing. Rare but well-documented signals: acute pancreatitis (uncertain causal contribution), severe joint pain, and bullous pemphigoid (class effect, especially in older Asian patients)'"`UNIQ--ref-00000763-QINU`"'. (1)

0.25 mg (1) · 10 mg PO once daily in the morning; 5 mg starting in heart failure (1) · 10 mg PO once daily, with or without food (1) · 100 mg at bedtime daily (1) · 100 mg PO once daily (50 mg if CrCl 30-44; 25 mg if <30 or dialysis) (1) · 2.5-5 mg PO once daily; titrate to 10 mg/d (1) · 5 mg PO at bedtime; may increase to 10 mg if inadequate (1) · 50 mg PO daily (25 mg in volume depletion or hepatic impairment) (1) · Formulation-dependent. Gels: 40–50 mg topically daily. Cypionate/enanthate IM: 50–100 mg weekly. Undecanoate IM: 750 mg q10w. Patch: 4 mg/d. (1)

0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 10 mg tablet; also as fixed-dose combinations with simvastatin (Vytorin) and atorvastatin (Liptruzet, withdrawn US 2015 but generics exist) (1) · 100 mg tabs (1) · 2.5, 5, 10 mg tablets; 1 mg/mL oral suspension (1) · 25 mg, 50 mg, 100 mg tablets (1) · 25, 50, 100 mg tablets; combination tablets with metformin (1) · 5 mg, 10 mg tablets (2) · Gels, patches, IM cypionate/enanthate/undecanoate, buccal tabs, nasal gel, oral undecanoate, subcutaneous pellets (1)

buccal (1) · IM (1) · nasal (1) · Oral (8) · oral (undecanoate only) (1) · Topical (gel/patch) (1)

30-60 min (immediate-release); 1-2 h (extended-release) (1) · BP effect 1-2 weeks; antihypertensive peak 3-6 weeks (1) · BP effect within 24 hours; full effect at 1-2 weeks (long half-life) (1) · Effects accumulate over weeks; assess at 8 weeks (1) · Glycosuria within hours; HbA1c effect at 12 weeks; CV/renal benefits over months (1) · Hours (transdermal); days (IM esters) (1) · LDL lowering within 2 weeks (1) · Postprandial glucose effect within days; HbA1c by 12 weeks (1) · ~30 min (1)

24 hours (5) · 6 h (immediate-release); ~11 h (extended-release) (1) · Continuous daily dosing (1) · Hours (nasal); ~24 h (gel/patch); 1–2 weeks (cypionate/enanthate IM); ~10 weeks (undecanoate IM) (1) · ~7-8 hours (1)

11-13 h (immediate-release); 11-16 h (extended-release) (1) · 2 hours (parent); 6-9 hours for active carboxylic acid metabolite EXP3174'"`UNIQ--ref-000000BC-QINU`"' (1) · 30-50 hours'"`UNIQ--ref-00000078-QINU`"' (1) · Highly variable by formulation; native T is hours (1) · ~11 h (1) · ~12.4 hours'"`UNIQ--ref-00000765-QINU`"' (1) · ~12.9 hours'"`UNIQ--ref-00000552-QINU`"' (1) · ~17-19 hours (longer than daridorexant) (1) · ~22 hours (parent + active glucuronide)'"`UNIQ--ref-00000450-QINU`"' (1)

64-90% (oral; not affected by food)'"`UNIQ--ref-00000079-QINU`"' (1) · 80-90% oral (1) · Oral non-undecanoate has essentially zero bioavailability (hepatic first-pass) (1) · Variable (oral; rapidly conjugated to active glucuronide; food does not affect)'"`UNIQ--ref-00000451-QINU`"' (1) · ~33% (1) · ~33% (extensive first-pass via CYP2C9 and CYP3A4)'"`UNIQ--ref-000000BD-QINU`"' (1) · ~44% (1) · ~78% (oral; high-fat meal modestly reduces but is not clinically significant)'"`UNIQ--ref-00000553-QINU`"' (1) · ~87% (oral)'"`UNIQ--ref-00000766-QINU`"' (1)

'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-000000BE-QINU`"' (1) · Avoid in second and third trimesters; fetal SGLT2 inhibition disrupts kidney development.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Category X, contraindicated; teratogenic (virilization of female fetus) (1) · Limited data; avoid (1) · Limited data; case series and registries suggest no major teratogenicity but other antihypertensives (labetalol, nifedipine) are typically preferred.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited data; generally avoided particularly in combination with statin.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited data; switch to insulin where feasible.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Not indicated; pregnancy effects unknown (1)

Rx, Schedule IV (US) (1) · Rx-only in US (REMS program) (1) · Schedule III (DEA, US) (1) · Schedule IV (US) (1) · [[USLegal:Prescription only|Rx-only]] in US (5)

Showing below up to 9 results in range #1 to #9.

A